

Zujiang Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3114173/publications.pdf>

Version: 2024-02-01

80
papers

3,000
citations

257450

24
h-index

189892

50
g-index

88
all docs

88
docs citations

88
times ranked

4202
citing authors

#	ARTICLE	IF	CITATIONS
1	Disturbance of hepatocyte growth and metabolism in a hyperammonemia microenvironment. Archives of Biochemistry and Biophysics, 2022, 716, 109109.	3.0	3
2	Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma. Disease Markers, 2022, 2022, 1-15.	1.3	2
3	Overlapping infection of Nocardia farcinica and Aspergillus fumigatus in a child with X-linked chronic granulomatous disease: a case report. BMC Infectious Diseases, 2022, 22, 69.	2.9	2
4	Clinical characteristics, outcome and prognostic factors in critically ill patients with lupus nephritis. Clinical and Experimental Rheumatology, 2022, 40, 514-521.	0.8	0
5	Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected With Delta or Omicron Variants. Journal of Infectious Diseases, 2022, 226, 1120-1122.	4.0	3
6	Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clinical Cancer Research, 2021, 27, 1003-1011.	7.0	334
7	MicroRNA-638 induces apoptosis and autophagy in human liver cancer cells by targeting enhancer of zeste homolog 2 (EZH2). Environmental Toxicology and Pharmacology, 2021, 82, 103559.	4.0	20
8	Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis. Lancet, The, 2021, 397, 1213.	13.7	10
9	Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut, 2021, 70, 1253-1265.	12.1	168
10	Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B. American Journal of Gastroenterology, 2021, 116, 1676-1685.	0.4	16
11	A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine, 2021, 67, 103389.	6.1	18
12	Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 656674.	3.9	16
13	Development of a Novel Simple Model to Predict Mortality in Patients With Systemic Lupus Erythematosus Admitted to the Intensive Care Unit. Frontiers in Medicine, 2021, 8, 689871.	2.6	2
14	RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 686547.	3.7	8
15	Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients. Orphanet Journal of Rare Diseases, 2021, 16, 58.	2.7	24
16	Expression and clinical significance of miR-3615 in hepatocellular carcinoma. Journal of International Medical Research, 2021, 49, 030006052098154.	1.0	7
17	Analysis of Multi-Layer RNA Modification Patterns for the Characterization of Tumor Immune Microenvironment in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 761391.	3.7	1
18	Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Frontiers in Physiology, 2021, 12, 715536.	2.8	11

#	ARTICLE	IF	CITATIONS
19	PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1495-1511.	3.7	15
20	Clinical characteristics, outcome and prognostic factors in critically ill patients with lupus nephritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
21	Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. <i>Journal of Cancer</i> , 2020, 11, 132-141.	2.5	13
22	Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2020, 9, 1254-1262.	2.8	5
23	A Metalâ€“Polyphenolâ€“Coordinated Nanomedicine for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy. <i>Advanced Materials</i> , 2020, 32, e1906024.	21.0	300
24	Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis. <i>Small</i> , 2020, 16, e1905233.	10.0	72
25	Characteristic of 523 COVID-19 in Henan Province and a Death Prediction Model. <i>Frontiers in Public Health</i> , 2020, 8, 475.	2.7	26
26	A Randomized, Openâ€“Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVIDâ€“19, a Pilot Study. <i>Advanced Science</i> , 2020, 7, 2001435.	11.2	89
27	Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 342.	3.9	39
28	Alterations of the Human Gut Microbiome in Chronic Kidney Disease. <i>Advanced Science</i> , 2020, 7, 2001936.	11.2	82
29	Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 15083.	3.3	49
30	<p>Transcriptome-Wide 5-Methylcytosine Functional Profiling of Long Non-Coding RNA in Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6877-6885.	1.9	19
31	Metabolomic Analysis of the Effects of Adipose-Derived Mesenchymal Stem Cell Treatment on Rats With Sepsis-Induced Acute Lung Injury. <i>Frontiers in Pharmacology</i> , 2020, 11, 902.	3.5	21
32	Light-triggered NO-releasing nanoparticles for treating mice with liver fibrosis. <i>Nano Research</i> , 2020, 13, 2197-2202.	10.4	18
33	The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 55.	3.7	97
34	A novel predicted model for hypertension based on a large cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 10615.	3.3	12
35	The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. <i>Arthritis Research and Therapy</i> , 2020, 22, 159.	3.5	11
36	Switching from Fatty Acid Oxidation to Glycolysis Improves the Outcome of Acuteâ€“Onâ€“Chronic Liver Failure. <i>Advanced Science</i> , 2020, 7, 1902996.	11.2	20

#	ARTICLE	IF	CITATIONS
37	Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 23.	3.7	10
38	Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 122, 983.	2.6	5
39	Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-17.	1.3	21
40	Circular RNA hsa_circ_0056836 functions as an oncogenic gene in hepatocellular carcinoma through modulating miR-766-3p/FOSL2 axis. <i>Aging</i> , 2020, 12, 2485-2497.	3.1	32
41	Identifying drug candidates for hepatocellular carcinoma based on differentially expressed genes. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 2664-2674.	0.0	0
42	Correlations between stemness indices for hepatocellular carcinoma, clinical characteristics, and prognosis. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5496-5510.	0.0	2
43	Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 1014-1023.	12.1	498
44	miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. <i>Cancer Cell International</i> , 2019, 19, 205.	4.1	28
45	Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. <i>Cancer Cell International</i> , 2019, 19, 211.	4.1	41
46	Long intergenic noncoding RNA SNHG16 interacts with miR-195 to promote proliferation, invasion and tumorigenesis in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2019, 383, 111501.	2.6	31
47	<p></p>Tumor suppressive functions of LZTFL1 in hepatocellular carcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5537-5544.	2.0	3
48	Vaccinia virus expressing IL-37 promotes antitumor immune responses in hepatocellular carcinoma. <i>Cell Biochemistry and Function</i> , 2019, 37, 618-624.	2.9	9
49	TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF- β signaling-mediated VEGF expression. <i>Cancer Management and Research</i> , 2019, Volume 11, 767-775.	1.9	14
50	Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. <i>Hepatology Research</i> , 2019, 49, 1097-1108.	3.4	37
51	miR-96 exerts carcinogenic effect by activating AKT/GSK-3 β -catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 38.	4.1	25
52	Overexpression of Pyruvate Dehydrogenase E1 α Subunit Inhibits Warburg Effect and Induces Cell Apoptosis Through Mitochondria-Mediated Pathway in Hepatocellular Carcinoma. <i>Oncology Research</i> , 2019, 27, 407-414.	1.5	38
53	A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00033.	2.5	5
54	The successful treatment for cardiac tamponade during radiofrequency ablation of hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 90-92.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1573-1582.	3.8	45
56	Protective effects of cilostazol on ethanol-induced damage in primary cultured hepatocytes. <i>Cell Stress and Chaperones</i> , 2018, 23, 203-211.	2.9	15
57	Hepatitis B virus X protein promotes proliferation of hepatocellular carcinoma cells by upregulating miR-181b by targeting INC5. <i>Biological Chemistry</i> , 2018, 399, 611-619.	2.5	7
58	NH4Cl affects the expression of Wnt/ β -catenin pathway in hepatocytes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 281-286.	1.4	0
59	miR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression. <i>Oncology Research</i> , 2018, 26, 1073-1081.	1.5	22
60	LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 101, 19-28.	2.8	76
61	Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure. <i>ACS Nano</i> , 2018, 12, 6536-6544.	14.6	109
62	MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF- β /Smad3 signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 168-176.	5.6	30
63	Coreopsis Tinctoria Modulates Lipid Metabolism by Decreasing Low-Density Lipoprotein and Improving Gut Microbiota. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1060-1074.	1.6	9
64	PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2017, 16, 4475-4482.	2.4	21
65	Hepatic injury is associated with cell cycle arrest and apoptosis with alteration of cyclin A and D1 in ammonium chloride-induced hyperammonemic rats. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 427-434.	1.8	13
66	Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. <i>Molecular Medicine Reports</i> , 2016, 14, 4042-4048.	2.4	61
67	The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer. <i>Tumor Biology</i> , 2016, 37, 6881-6891.	1.8	12
68	Dynamic changes in CD45RA ⁺ Foxp3 ^{high} regulatory T-cells in chronic hepatitis C patients during antiviral therapy. <i>International Journal of Infectious Diseases</i> , 2016, 45, 5-12.	3.3	7
69	Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. <i>Oncotarget</i> , 2016, 7, 38333-38346.	1.8	54
70	Poly (ADP-ribose) polymerase- and cytochrome c-mediated apoptosis induces hepatocyte injury in a rat model of hyperammonia-induced hepatic failure. <i>Molecular Medicine Reports</i> , 2015, 11, 4211-4219.	2.4	5
71	The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 2215.	2.0	5
72	Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth. <i>Scientific Reports</i> , 2015, 5, 10433.	3.3	43

#	ARTICLE	IF	CITATIONS
73	Lowering blood ammonia prevents hepatocyte injury and apoptosis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 12347-55.	1.3	4
74	In vitro effects of mitomycin C on the proliferation of the non-small-cell lung cancer line A549. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 20516-23.	1.3	7
75	The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α -2b. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2015, 28, 1493-7.	0.2	3
76	The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma. <i>Discovery Medicine</i> , 2015, 20, 311-24.	0.5	9
77	Role of MicroRNA-1 in Human Cancer and Its Therapeutic Potentials. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	61
78	Ammonia-induced energy disorders interfere with bilirubin metabolism in hepatocytes. <i>Archives of Biochemistry and Biophysics</i> , 2014, 555-556, 16-22.	3.0	24
79	Heparin inhibits burn-induced spleen cell apoptosis by suppressing interleukin-1 expression. <i>Chinese Medical Journal</i> , 2014, 127, 2463-9.	2.3	1
80	A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. <i>Hepatology International</i> , 2012, 6, 441-448.	4.2	17